// App-Quantinova.ai

EP595 : EFFECT OF PEGCETACOPLAN ON QUALITY OF LIFE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: WEEK 48 OF PEGASUS PHASE 3 TRIAL COMPARING PEGCETACOPLAN TO ECULIZUMAB

Researchers

Presenter

  • Alexander Rth

Principal Investigators

  • Britta Hchsmann

  • Morag Griffin

  • Carlos M. de Castro

  • Jeffrey Szer

  • Kensuke Usuki

  • Juliette Soret

  • Mohammed Al-Adhami

  • Crystal Chen

  • Sujata P. Sarda

  • Jens Panse

Medical Centers

  • Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

  • Royal Melbourne Hospital, Melbourne, Australia

  • Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

  • Duke University, Durham, North Carolina, United States

  • Assistance Publique-Hôpitaux de Paris, University Paris 7, Paris, France

  • Apellis Pharmaceuticals, Inc.,Waltham,United States

  • University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics,German Red Cross Blood Transfusion Service and University Hospital Ulm, Institute of Transfusion Medicine,Ulm,Germany

  • Centre -Investigations Cliniques, Hopital Saint-Louis, Paris, France

  • Department of Oncology, Hematology and Stem Cell Transplantation, University Hospital of the RWTH Aachen, Aachen, Germany

  • Department of Clinical Haematology,Peter MacCallum Cancer Centre &amp

Locations

  • Germany

  • Australia

  • Japan

  • United States

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Superiority

  • Controlled

Phase

  • III

Study Id's

  • NCT03500549

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved